ITM_Logo_Claim_RGB_high-res.png
ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing
June 06, 2024 05:00 ET | ITM Isotope Technologies Munich SE
Proceeds to support development of ITM’s targeted radiopharmaceutical pipeline and preparations for potential market launch of phase III lead candidate, ITM-11, as it nears clinical read-out Funds...
Global Oncolytic Virotherapy Market
Global Oncolytic Virotherapy Market Research 2024: Industry Size, Share, Trends, Opportunity & Forecasts, 2019-2029 - Focus on Personalized Medicine, Clinical Advancements Spurs Growth
May 14, 2024 10:24 ET | Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Oncolytic Virotherapy Market - Global Industry Size, Share, Trends, Opportunity & Forecast, 2019-2029F" report has been added to ...
Global Precision Oncology Market
$163 Billion Precision Oncology Markets - Global Industry Size, Share, Trends, Opportunity & Forecast, 2019-2023 & 2024-2029F
May 14, 2024 02:52 ET | Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Precision Oncology Market - Global Industry Size, Share, Trends, Opportunity & Forecast, 2019-2029F" report has been added to ...
Global Metagenomics Market
Metagenomics Market Size, Share & Trends Analysis Report 2024-2030: Emergence of New Fields in Genomics that Complement Metagenomics Fueling Expansion
May 13, 2024 10:02 ET | Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "Metagenomics Market Size, Share & Trends Analysis Report By Technology (Shotgun Sequencing, Whole Genome Sequencing), By Product, By Workflow, By...
GENE logo.png
New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
April 17, 2024 08:00 ET | Genetic Technologies Ltd
New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
ptx-logo .png
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
April 09, 2024 16:35 ET | Prelude Therapeutics, Inc.
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9...
22157.jpg
Global Orphan Drug Sector Poised for Growth Amidst Unmet Rare Disease Needs
April 05, 2024 04:04 ET | Research and Markets
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "Global Orphan Drug Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. This study provides critical insights into the...
22157.jpg
Innovation Waves in Immuno-oncology Therapy Development - Next-gen Cell Therapies and Precision Immunotherapies are Driving Growth and New Product Development
March 21, 2024 05:13 ET | Research and Markets
Dublin, March 21, 2024 (GLOBE NEWSWIRE) -- The "Innovation Waves in Immuno-oncology Therapy Development" report has been added to ResearchAndMarkets.com's offering. Immuno-oncology (I-O)...
Omics Lab Services Market
Omics Lab Services Market Forecast Report 2024-2029: 15% CAGR Forecast During 2024-2029, with Notable Developments in Cancer Research and Genomics
March 15, 2024 05:09 ET | Research and Markets
Dublin, March 15, 2024 (GLOBE NEWSWIRE) -- The "Omics Lab Services Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's offering.The omics lab services market was...
aignostics logo_color14_new.png
Bayer and Aignostics to collaborate on next generation precision oncology
March 14, 2024 03:30 ET | Aignostics GmbH
Not intended for UK Media Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development, further strengthening Bayer’s...